This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.

Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

GLP-1 medications in District of Columbia: Medicaid coverage, cost and access

Q: Does District of Columbia Medicaid cover Wegovy or Zepbound for weight loss?

We hold no dated District of Columbia bulletin and will not guess. Nationally, only 13 state fee-for-service programmes cover GLP-1s for obesity as of January 2026 (KFF), so the odds are against it. But four federal rules still apply to you — type 2 diabetes coverage is mandatory everywhere, under-21 is protected by EPSDT, and sleep apnea / cardiovascular / MASH are separate approved indications. Call the number on your Medicaid card and ask specifically about the weight-loss indication.

Direct answer

What we evaluated: District of Columbia’s Medicaid position on GLP-1s for obesity, and what the treatment costs there
Date verified: January 2026 (KFF); state actions through April 2026
Direct answer: We hold no dated District of Columbia bulletin on weight-loss GLP-1 coverage, and we will not guess. Nationally, only 13 state fee-for-service programmes cover GLP-1s for obesity (KFF, January 2026), so the odds are against it — but four federal rules still give you a path regardless of what District of Columbia decided. Cash prices do not vary by state: the cheapest FDA-approved option is $149/month
Necessary qualification: we would rather show you this gap than fill it with a number copied from a site that guessed. Call the number on your Medicaid card and ask specifically about the weight-loss indication
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.

Before you conclude you have no path

Four federal rules that apply in every stateWhatever your state decided, four federal rules still apply to you. (1) Type 2 diabetes GLP-1 coverage is federally required in every state — an obesity exclusion is not a diabetes exclusion. (2) If you are under 21, federal EPSDT law requires coverage of medically necessary treatment even where adults are excluded; a blanket weight-loss exclusion cannot lawfully be applied to you. (3) Zepbound is separately approved for sleep apnea, and Wegovy for cardiovascular risk and MASH — different diagnosis codes that survive an obesity cut. (4) Every covering state requires prior authorisation.

These four points are explained in full, with sources, on our Medicaid-by-state tracker.

District of Columbia in context

Adult obesity prevalence in District of Columbia is 25.5% (CDC). Among District of Columbia’s neighbouring states, Virginia does cover GLP-1s for obesity under Medicaid. Nationally, 13 state Medicaid fee-for-service programmes covered GLP-1s for obesity as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all cut coverage on 1 January. Massachusetts is scheduled to end coverage on 1 July 2026. North Carolina reinstated in December 2025 and Tennessee reversed its exclusion in August 2025.

Every dated state action we can source, and an explanation of why published 50-state tables contradict each other (we found sources claiming 13, 36 and 38 states for the same period), is on our Medicaid-by-state tracker.

An honest note about this pageWhy this page is short. We could pad it to two thousand words, and many sites do. But we hold no District of Columbia-specific bulletin, and cash prices are identical in every state — so a longer page would be the same national content with the state name swapped in. That is not research, and search engines are right to treat it as spam. We would rather give you the four federal rules that actually apply to you, tell you plainly what we do not know, and send you to the pages that hold the real detail.

What GLP-1 treatment costs in District of Columbia

Cash pricing does not vary by state, so rather than reprint the national tables here, we keep them in one place and keep them current: the full pricing database (86 offerings across 18 providers, sorted on total monthly cost).

What cash actually costs, wherever you liveThe headline you need: the cheapest FDA-approved option is now $149/month — the Foundayo oral pill via LillyDirect, or the oral Wegovy tablet via NovoCare. Both undercut most of the compounded market. The cheapest compounded totals are $110 (NexLife semaglutide microdose) and $133 (Oak Longevity, though Oak does not serve California).

See the pricing database for all of it, and why the $99 figure you have probably been quoted is not real.

Verifying a compounding pharmacy licensed in District of Columbia

If you use a compounded GLP-1, the pharmacy matters more than the brand on the telehealth website. Compounded medications are dispensed by state-licensed pharmacies, and the District of Columbia Board of Pharmacy publishes a licensee database you can search.

Ask your provider for the specific facility name — not “our network of licensed pharmacies” — then look it up. Also ask whether it is a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility; these are different regulatory categories, and registration is per-facility, not per-company. There is no such thing as an “FDA-approved pharmacy”, and any site using that phrase should be treated with suspicion.

Our full pharmacy-evaluation checklist →

Our verification gapWhat we have not verified in District of Columbia. We have not audited state licensure for any provider on this site, and we have not confirmed the pharmacy licences behind any programme. Every pharmacy claim we publish is provider-reported. We would rather show you that gap than paper over it.

Frequently asked questions

Does District of Columbia Medicaid cover Wegovy or Zepbound for weight loss?

We hold no dated District of Columbia bulletin and will not guess. Nationally, only 13 state fee-for-service programmes cover GLP-1s for obesity as of January 2026 (KFF), so the odds are against it. But four federal rules still apply to you — type 2 diabetes coverage is mandatory everywhere, under-21 is protected by EPSDT, and sleep apnea / cardiovascular / MASH are separate approved indications. Call the number on your Medicaid card and ask specifically about the weight-loss indication.

What is the cheapest GLP-1 option in District of Columbia?

The same as everywhere else — cash pricing does not vary by state. The cheapest FDA-approved option is $149/month (Foundayo oral pill via LillyDirect, or the oral Wegovy tablet via NovoCare). The cheapest compounded totals are $110 and $133/month. See our pricing database.

Can I use a telehealth GLP-1 provider in District of Columbia?

Every provider we track states availability in District of Columbia, with two national exceptions worth knowing: Oak Longevity does not serve California, and bmiMD charges $379.99 in California and North Carolina versus $289 elsewhere. We have not independently audited state licensure for any provider.

Sources

KFF — "Medicaid Coverage of and Spending on GLP-1s", January 2026. The 13-state count.
District of Columbia Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence in District of Columbia.
CDC — adult obesity prevalence by state.
Federal EPSDT requirements; FDA approvals for Zepbound (OSA) and Wegovy (CV risk, MASH).
Our Medicaid-by-state tracker and pricing database.

Spotted an error? Submit a correction.